Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771958 | 0.92 | MAP4K4 (0.35) | FFAR4MAP4K4CCNT1CDK2CDK9 | |
| SCHEMBL3843144 | 0.90 | ABL1 (0.34) | SLC22A12 | |
| SCHEMBL3773176 | 0.88 | EGLN1 (0.38) | SLC22A12 | |
| SCHEMBL3765795 | 0.81 | ALDH1A1 (0.31) | — | |
| SCHEMBL3145780 | 0.81 | MAP4K4 (0.34) | FFAR4USP28MAP4K4CCNT1CDK2 | |
| SCHEMBL3770601 | 0.77 | CCNT1 (0.34) | FFAR4MAP4K4CCNT1CDK2CDK9 | |
| SCHEMBL3781385 | 0.74 | FFAR4 (0.38) | FFAR4MAP4K4 | |
| SCHEMBL3779166 | 0.74 | FFAR4 (0.38) | FFAR4MAP4K4 | |
| SCHEMBL3141366 | 0.74 | SYK (0.37) | CCNT1CDK2CDK9 | |
| SCHEMBL3782751 | 0.74 | FFAR4 (0.41) | FFAR4MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | FFAR4 110/4885USP28 3661/4885MAP4K4 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.